MedTrace Logo

Safety and PK of Multiple Doses of MT1988

NCT06728176 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-04-17

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the tolerability and amount of drug in the blood when four dose levels of MT1988 are administered for 14 days to healthy volunteers. The main question it aims to answer is:

* what side effects are seen while administering MT1988 for 14 days?
* how much of MT1988 can be measured in the blood at the beginning and end of administering MT1988 for 14 days?

Researchers will include a placebo arm (dummy drug) to compare the side effects.

Participants will:

* take MT1988 every day for 14 days
* visit the clinic once per week for assessments
* keep a diary to record information between clinic appointments.

Conditions

  • Healthy Volunteer

Interventions

DRUG

MT1988

Active Drug

DRUG

Placebo

Placebo comparator

Sponsors & Collaborators

  • Monument Therapeutics Limited

    lead INDUSTRY

Principal Investigators

  • Medical Director · BDD Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-25
Primary Completion
2025-04-08
Completion
2025-04-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06728176 on ClinicalTrials.gov